Arrowhead Pharmaceuticals (ARWR) Scheduled to Post Quarterly Earnings on Tuesday

Arrowhead Pharmaceuticals (NASDAQ:ARWR) is scheduled to be posting its quarterly earnings results after the market closes on Tuesday, November 26th. Analysts expect Arrowhead Pharmaceuticals to post earnings of ($0.63) per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

Arrowhead Pharmaceuticals Stock Performance

Shares of ARWR opened at $18.54 on Friday. Arrowhead Pharmaceuticals has a fifty-two week low of $17.05 and a fifty-two week high of $39.83. The stock has a fifty day moving average of $19.86 and a two-hundred day moving average of $23.22. The company has a market capitalization of $2.30 billion, a PE ratio of -3.97 and a beta of 0.93.

Analysts Set New Price Targets

A number of brokerages have issued reports on ARWR. StockNews.com raised Arrowhead Pharmaceuticals to a “sell” rating in a research note on Tuesday, November 12th. Piper Sandler reissued an “overweight” rating and issued a $62.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, October 8th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arrowhead Pharmaceuticals in a research report on Monday, September 9th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $42.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Thursday, September 26th. Finally, B. Riley reissued a “buy” rating and set a $55.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Monday, August 12th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, Arrowhead Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $45.33.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.